Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

AVANIR Pharmaceuticals Invites Investors to Listen to the Jefferies Life Science Conference Webcast.


SAN DIEGO -- AVANIR Pharmaceuticals (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:AVNR AVNR Atrioventricular Nodal Reentry ) will be presenting at the Jefferies Life Science Conference on Tuesday, June 27, 2006 at 4:30 p.m. EST in New York New York, state, United States
New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of
. AVANIR's Vice President, Business Development and Portfolio Management, Marty Emanuele, Ph.D., will be presenting at the investor conference.

The presentation will be available via a live webcast accessible through AVANIR's corporate website at www.avanir.com. To access the webcast, log on to AVANIR's site fifteen minutes prior to the presentation to register and download any necessary audio software. An archive of the presentation will be available 90 days following the event.

About AVANIR

AVANIR Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system, cardiovascular disorders, inflammation and infectious diseases. AVANIR currently markets FazaClo(R), the only orally-disintegrating formulation of clozapine clozapine /clo·za·pine/ (klo´zah-pen) a sedative and antipsychotic agent; used in the treatment of schizophrenia.

clo·za·pine
n.
 for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenic drug treatments. FazaClo is also indicated for reducing the risk of suicidal behavior in patients with schizophrenic or schizoaffective disorder Schizoaffective Disorder Definition

Schizoaffective disorder is a mental illness that shares the psychotic symptoms of schizophrenia and the mood disturbances of depression or bipolar disorder.
. For full prescribing information and important safety information regarding FazaClo, please visit www.fazaclo.com. AVANIR's lead product candidate, Neurodex(TM) for the treatment of involuntary emotional expression disorder, is the subject of a New Drug Application under priority review with the FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
. Additionally, AVANIR has initiated a Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the  with Neurodex as a potential treatment for patients with painful diabetic neuropathy. AVANIR has active collaborations with two international pharmaceutical companies: Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease and AstraZeneca for the treatment of cardiovascular disease. The Company's first commercialized product, abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 14, 2006
Words:319
Previous Article:Medical Capital Advisors Co-Sponsoring Medtech Insight and Windhover Information's ``In3 Medical Device Summit'' Conference, June 21-23, 2006, in San...
Next Article:New Forward Concepts Study Indicates That Cellphones Have Become the Largest Audio Chip Market.



Related Articles
Avanir Pharmaceuticals to Announce Third Fiscal Quarter 2002 Results On August 13.
AVANIR Announces September 28 Webcast of Investment Community Meeting.
AVANIR Pharmaceuticals Invites Investors to the Bank of America and the UBS Global Life Sciences Conference Webcasts.
AVANIR Pharmaceuticals Invites Investors to the Lazard Capital Markets Life Sciences Conference Webcast.
AVANIR Pharmaceuticals Invites Investors to Its Fourth Quarter and Fiscal 2005 Conference Call on December 5, 2005.
AVANIR Pharmaceuticals Invites Investors to Its First Quarter Conference Call on Thursday, February 9, 2006.
AVANIR Pharmaceuticals Invites Investors to Its Second Quarter Conference Call on Monday, May 8, 2006.
AVANIR Pharmaceuticals Invites Investors to Listen to the Bank of America 2006 Health Care Conference Webcast.
AVANIR Pharmaceuticals Invites Investors to Listen to the 2006 UBS Global Life Sciences Conference Webcast.
AVANIR Pharmaceuticals Invites Investors to Listen to the Lazard Capital Markets 3rd Annual Life Sciences Conference Webcast.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles